Clinical trial

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

NCT04211896

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2020-01-01

PhasePHASE2

Study timeline

Study start (estimated)2020-01-01Date precision: day

Registry last updated2019-12-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

AnlotinibDRUG

NivolumabDRUG · verified · RxNorm: nivolumab

Sponsors & collaborators

The First Affiliated Hospital with Nanjing Medical Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04211896 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.